Myriad Gets $100M Upfront in European Deal for Flurizan

tmcnet.com     22-May-2008            

250M Potential As its Flurizan product nears what could be a multi-billion dollar market in Alzheimer's disease, Myriad Genetics Inc. launched its global strategy by signing a commercialization deal in Europe with J. Lundbeck AS for $100 million upfront with a potential for $250 million. Myriad... [read full story]                    


*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies